160 related articles for article (PubMed ID: 25487540)
1. KRAS mutation testing in clinical practice.
Perincheri S; Hui P
Expert Rev Mol Diagn; 2015 Mar; 15(3):375-84. PubMed ID: 25487540
[TBL] [Abstract][Full Text] [Related]
2. KRAS and BRAF: drug targets and predictive biomarkers.
Vakiani E; Solit DB
J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutation testing in colorectal cancer.
Plesec TP; Hunt JL
Adv Anat Pathol; 2009 Jul; 16(4):196-203. PubMed ID: 19546608
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.
Wang HL; Lopategui J; Amin MB; Patterson SD
Adv Anat Pathol; 2010 Jan; 17(1):23-32. PubMed ID: 20032635
[TBL] [Abstract][Full Text] [Related]
5. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
7. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective.
Ross JS
Arch Pathol Lab Med; 2012 Oct; 136(10):1298-307. PubMed ID: 22272560
[TBL] [Abstract][Full Text] [Related]
8. Should oncologists be aware in their clinical practice of KRAS molecular analysis?
Santini D; Galluzzo S; Gaeta L; Zoccoli A; Riva E; Ruzzo A; Vincenzi B; Graziano F; Loupakis F; Falcone A; Muda AO; Tonini G
J Clin Oncol; 2011 Mar; 29(8):e206-7; author reply e208-9. PubMed ID: 21263083
[No Abstract] [Full Text] [Related]
9. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
10. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
11. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
[No Abstract] [Full Text] [Related]
12. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.
Domagała P; Hybiak J; Sulżyc-Bielicka V; Cybulski C; Ryś J; Domagała W
Pol J Pathol; 2012 Nov; 63(3):145-64. PubMed ID: 23161231
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13.
Bihl MP; Hoeller S; Andreozzi MC; Foerster A; Rufle A; Tornillo L; Terracciano L
Diagn Mol Pathol; 2012 Mar; 21(1):14-23. PubMed ID: 22306671
[TBL] [Abstract][Full Text] [Related]
15. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
16. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
17. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
Blank PR; Moch H; Szucs TD; Schwenkglenks M
Clin Cancer Res; 2011 Oct; 17(19):6338-46. PubMed ID: 21807639
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?
Scott RJ; Fox SB; Desai J; Grieu F; Amanuel B; Garrett K; Harraway J; Cheetham G; Pattle N; Haddad A; Byron K; Rudzki B; Waring P; Iacopetta B
Asia Pac J Clin Oncol; 2014 Sep; 10(3):261-5. PubMed ID: 24811330
[TBL] [Abstract][Full Text] [Related]
19. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.
Wagner PL; Stiedl AC; Wilbertz T; Petersen K; Scheble V; Menon R; Reischl M; Mikut R; Rubin MA; Fend F; Moch H; Soltermann A; Weder W; Altorki NK; Perner S
Lung Cancer; 2011 Oct; 74(1):118-23. PubMed ID: 21477882
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
